Can Zimmer Biomet Recover after Disappointing 3Q17?

1 2 3 4 5 6 7 8 9 10
Part 5
Can Zimmer Biomet Recover after Disappointing 3Q17? PART 5 OF 10

Asia-Pacific Still Zimmer Biomet’s Strongest Geography

ZBH’s geographic footprints

Zimmer Biomet Holdings has a presence around the globe and is a leading developer and manufacturer of musculoskeletal implants technology. It has a total of 39 manufacturing facilities worldwide. It sells its products in more than 100 countries. In 3Q17, its sales fell 0.4% in the Europe, Middle East, and Africa region on a constant currency basis. Its US sales fell 3% on a constant currency basis. However, in the Asia-Pacific region, ZBH reported sales growth of 5.2% on a constant currency basis.

Asia-Pacific Still Zimmer Biomet&#8217;s Strongest Geography

Interested in ZBH? Don't miss the next report.

Receive e-mail alerts for new research on ZBH

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Asia-Pacific performance drivers

Zimmer Biomet Holdings witnessed a strong performance in its Asia-Pacific region. It contributed 16% to the company’s total sales compared to a 63% contribution from US sales and 21% from Europe. Asia-Pacific sales of $295 million had a positive impact of 2.8% on favorable foreign currency. The company’s knee sales in the Asia-Pacific region rose 3.9%, while its hip sales rose 6.1% on a constant currency basis. The company’s strong Asia-Pacific sales performance came despite pricing cuts in India for knee implants. However, operating profits in Asia-Pacific fell in the quarter.

Zimmer Biomet Holdings is the leader in the Asia-Pacific orthopedic joint replacement device market, followed by Stryker (SYK), DePuy Synthes (a subsidiary of Johnson & Johnson (JNJ)), and Smith & Nephew (SNN). For exposure to Zimmer Biomet Holdings, conservative investors looking to diversify company-specific risks can consider investing in the iShares Russell Mid-Cap (IWR), which has 0.34% of its total portfolio holdings in ZBH.

Next, let’s look at the company’s operational plans for the revival of its sales growth going forward.


Please select a profession that best describes you: